How were AveXis' earnings last quarter?

AveXis, Inc. (NASDAQ:AVXS) released its earnings results on Wednesday, May, 9th. The company reported ($6.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.32) by $2.88.

What other stocks do shareholders of AveXis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AveXis investors own include REGENXBIO (RGNX) , bluebird bio (BLUE) , Exelixis (EXEL) , Mallinckrodt (MNK) , AbbVie (ABBV) , Salesforce (CRM) , CRISPR Therapeutics (CRSP) , Editas Medicine (EDIT) , Momenta Pharmaceuticals (MNTA) and Neurocrine Biosciences (NBIX) .

AveXis (AVXS) raised $86 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 4,300,000 shares at $19.00-$21.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and BMO Capital Markets and Chardan were co-managers.

NASDAQ:AVXS

AveXis (AVXS) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free AVXS Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $217.83
▼
$217.83
50-Day Range: N/A
52-Week Range: $65.54
▼
$217.94

Volume: 222 shs
Average Volume: 816,305 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get AveXis alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About AveXis Stock (NASDAQ:AVXS)

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. The company also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases. It has strategic collaboration and license agreements with Nationwide Children's Hospital; The Research Institute at Nationwide Children's Hospital; REGENXBIO Inc.; and Asklepios Biopharmaceutical, Inc. The company was formerly known as BioLife Cell Bank, Inc. and changed its name to AveXis, Inc. in January 2014. AveXis, Inc. was founded in 2010 and is headquartered in Bannockburn, Illinois.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

AVXS Stock News Headlines

May 25, 2023 | finance.yahoo.com

Novartis ‘focusing on high-end, innovative medicines,’ CEO says

January 2, 2023 | thestreet.com

Ionis Childhood Spine Disorder Drug Notches Pivotal Study Win, Triggers Biogen Option

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

September 21, 2022 | bizjournals.com

Google-backed gene therapy firm launches Morrisville manufacturing facility - The Business Journals

September 15, 2022 | seekingalpha.com

Regenxbio Stock: A Transformative Year (NASDAQ:RGNX) - Seeking Alpha

September 12, 2022 | finance.yahoo.com

GenSight Biologics Strengthens Its Management Team to Support the Launch of LUMEVOQ® in Europe - Yahoo Finance

August 29, 2022 | seekingalpha.com

REGENXBIO: Gene Therapy Pioneer Moving To Late-Stage Development (NASDAQ:RGNX) - Seeking Alpha

August 29, 2022 | dallasnews.com

Once high-flying Dallas biotech sees promising drug data amid growing financial pressure - The Dallas Morning News

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

August 20, 2022 | bizjournals.com

It's in our DNA: Why the Columbus Region is a hub for gene therapy companies - Columbus Business First - The Business Journals

August 17, 2022 | streetinsider.com

Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access - StreetInsider.com

July 20, 2022 | prnewswire.com

July 18, 2022 | globenewswire.com

Generation Bio Appoints Dannielle Appelhans to Its Board of Directors - GlobeNewswire

June 9, 2022 | finance.yahoo.com

Global Cell and Gene Therapy Market Analysis/Opportunities Report 2022-2035: Niche Startups are Spearheading the Innovation in this Domain - Yahoo Finance

June 9, 2022 | prnewswire.com

Global Cell and Gene Therapy Market Analysis/Opportunities Report 2022-2035: Niche Startups are Spearheading the Innovation in this Domain - PR Newswire

June 8, 2022 | globenewswire.com

Global Cell and Gene Therapy Market Investor/Opportunities Report 2022: Evaluate the Current/Future Potential Over the Coming Decades - GlobeNewswire

June 7, 2022 | seekingalpha.com

BLUE stock drives gene therapy stocks higher after FDA review (NASDAQ:BLUE) - Seeking Alpha

May 3, 2022 | finance.yahoo.com

Sumo Logic Appoints John D. Harkey, Jr. to Board of Directors - Yahoo Finance

April 21, 2022 | streetinsider.com

Satellite Bio Reveals Pioneering Tissue Therapeutics, Bioengineered Tissues That Restore Organ Function, Bringing Hope Across Diseases - StreetInsider.com

April 20, 2022 | seekingalpha.com

Regenxbio: Is The Ultimate Catalyst Coming? - Seeking Alpha

April 20, 2022 | businesswire.com

Satellite Bio Reveals Pioneering Tissue Therapeutics, Bioengineered Tissues That Restore Organ Function, Bringing Hope Across Diseases - Business Wire

March 29, 2022 | bizjournals.com

Samsung invests in Chicago biotech Jaguar Gene Therapy - The Business Journals

March 29, 2022 | finance.yahoo.com

Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors - Yahoo Finance

March 9, 2022 | finance.yahoo.com

TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities - Yahoo Finance

March 7, 2022 | seekingalpha.com

Taysha Gene Therapies Gets A 'Thumbs Up' - Seeking Alpha

March 5, 2022 | theguardian.com

'It's a real-life Hunger Games': a lifesaving drug costs $2m, but not every child can get it - The Guardian

February 14, 2022 | prnewswire.com

NEW STATE AVIATION HOLDINGS NAMES CEO AND CFO - PRNewswire

See More Headlines

Receive AVXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AveXis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/09/2018
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological Products, Except Diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:AVXS
CUSIP: N/A
CIK: 1652923
Web: www.avexis.com
Phone: 847-572-8280
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Optionable
Beta: N/A

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Sean P. Nolan (Age 50)
Chief Exec. Officer, Pres and Director
Dr. Sukumar Nagendran M.D. (Age 51)
Chief Medical Officer and Sr. VP
Mr. Phillip B. Donenberg CPA (Age 57)
Sr. VP, CFO & Principal Accounting Officer
Mr. Brian K. Kaspar Ph.D. (Age 44)
Chief Scientific Officer, Director and Member of Scientific Advisory Board
Mr. Michael B. Johannesen (Age 52)
Chief Compliance Officer, Sr. VP and Gen. Counsel

Key Competitors

View All Competitors

AVXS Stock Analysis - Frequently Asked Questions

How were AveXis' earnings last quarter?: AveXis, Inc. (NASDAQ:AVXS) released its earnings results on Wednesday, May, 9th. The company reported ($6.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.32) by $2.88.
What other stocks do shareholders of AveXis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AveXis investors own include REGENXBIO (RGNX), bluebird bio (BLUE), Exelixis (EXEL), Mallinckrodt (MNK), AbbVie (ABBV), Salesforce (CRM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA) and Neurocrine Biosciences (NBIX).
When did AveXis IPO?: AveXis (AVXS) raised $86 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 4,300,000 shares at $19.00-$21.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and BMO Capital Markets and Chardan were co-managers.

This page (NASDAQ:AVXS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AveXis (AVXS) Stock Price, News & Analysis

About AveXis Stock (NASDAQ:AVXS)

AVXS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

AVXS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info